Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 3 for:    Carotid Endarterectomy | Open Studies | NIH, U.S. Fed
Previous Study | Return to List | Next Study

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Mayo Clinic
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas G. Brott, M.D., Mayo Clinic
ClinicalTrials.gov Identifier:
NCT02089217
First received: March 13, 2014
Last updated: February 24, 2015
Last verified: February 2015
  Purpose

Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed.


Condition Intervention
Carotid Stenosis
Procedure: Carotid endarterectomy
Device: Carotid stenting

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Stroke and death [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The primary outcome is the composite of stroke plus death within 44 days after randomization and ipsilateral stroke thereafter up to 4 years.


Secondary Outcome Measures:
  • Cognitive Function [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The assess if MEDICAL management differs from CAS, and differs from CEA, to maintain the level of cognitive function at the 4-year assessment.

  • Major Stroke [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    if there are treatment differences in the incidence of major stroke at 4-years among all arms of the study

  • Effect modification [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Potential effect modification of the CAS or CEA versus MEDICAL differences, based on patient age, sex, severity of carotid stenosis, restenosis, risk factor level, and duration of asymptomatic period.


Estimated Enrollment: 2480
Study Start Date: December 2014
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Carotid Endarterectomy (CEA)
Carotid endarterectomy
Procedure: Carotid endarterectomy
Active Comparator: Carotid Stenting (CAS)
Carotid stenting
Device: Carotid stenting
No Intervention: Medical
Intensive medical management

Detailed Description:

Prevention of stroke involves managing and treating risk factors. Most strokes are caused when blood flow to a portion of the brain is blocked. One place this often happens is in the carotid artery. This blockage is called atherosclerosis or hardening of the arteries.

The purpose of this trial is to determine the best way to prevent strokes in people who have a high amount of blockage of their carotid artery but no stroke symptoms related to that blockage. Each eligible participant will be evaluated to determine which procedure(s) is best for him/her. All participants will receive intensive medical treatment. In addition, participants will be randomized to receive the selected procedure or not.

The trial will be conducted in the United States and Canada by physicians carefully selected on their ability to perform the procedures at low risk. Another key component of the trial is that important stroke risk factors, including hypertension, diabetes, high cholesterol, cigarette smoking, physical activity, and diet will be managed intensively. Participants will remain in the study for 4 years.

  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria

  1. Patients ≥ 35 years old.
  2. Carotid stenosis defined as: stenosis ≥ 70% by angiography (NASCET Criteria); or by DUS with ≥ 70% stenosis defined by a peak systolic velocity of at least 230 cm/s and an end diastolic velocity ≥ 100 cm/s, or internal carotid/ common carotid artery peak systolic velocity ratio ≥ 4.0, or by a peak systolic velocity on DUS ≥ 230 cm/s plus CTA or MRA confirmation.
  3. No medical history of stroke or TIA ipsilateral to the stenosis within 180 days of randomization. Life-long asymptomatic patients will be defined as having no medical history of stroke or transient ischemic attack and negative responses to all of the symptom items on the Questionnaire for Verifying Stroke-free Status (QVSS).
  4. Patients must have a modified Rankin score of 0 or 1 at the time of informed consent.
  5. Women must not be of childbearing potential or, if of childbearing potential, have a negative pregnancy test prior to randomization.
  6. Patients must agree to comply with all protocol-specified follow-up appointments.
  7. Patients must sign a consent form that has been approved by the local governing Institutional Review Board (IRB)/Medical Ethics Committee (MEC) of the respective clinical site.
  8. Randomization to treatment group will apply to only one carotid artery for patients with bilateral carotid stenosis. Management of the non-randomized stenosis may be done in accordance with local PI recommendation. Treatment of the non-study internal carotid artery must take place at least 30 days prior to randomization, or at least 30 days after the study procedure is completed.
  9. Carotid stenosis must be treatable with CEA, CAS, or either procedures.

General Exclusion Criteria

  1. Intolerance or allergic reaction to a study medication without a suitable alternative.
  2. GI hemorrhage within 1 month prior to enrollment that would preclude antiplatelet therapy.
  3. Major ipsilateral stroke in the past with substantial residual disability (mRS ≥ 2) that is likely to confound study outcomes.
  4. Severe dementia.
  5. Intracranial hemorrhage within the past 12 months.
  6. Neurologic illness characterized by fleeting or fixed neurologic deficits that cannot be distinguished from TIA or stroke.
  7. Patient objects to future blood transfusions.
  8. Platelet count < 100,000/microliter, uncorrected INR > 1.5, bleeding time > 1 minute beyond upper limit normal (at screening), or history of heparin-induced thrombocytopenia.
  9. Anticoagulation with Phenprocoumon, warfarin, or a direct thrombin inhibitor.
  10. Chronic atrial fibrillation.
  11. Any episode of atrial fibrillation within the past 6 months or history of paroxysmal atrial fibrillation that is deemed to require chronic anticoagulation.
  12. Other high-risk cardiac sources of emboli, including left ventricular aneurysm, severe cardiomyopathy, aortic or mitral mechanical heart valve, severe calcific aortic stenosis (valve area < 1.0 cm2), endocarditis, moderate to severe mitral stenosis, left atrial thrombus, or any intracardiac mass.
  13. Unstable angina defined as rest angina with ECG changes that is not amenable to revascularization (patients should undergo planned coronary revascularization at least 30 days before randomization).
  14. Ejection fraction < 30% or admission for heart failure in prior 6 months.
  15. Respiratory insufficiency with life expectancy < 4 years or FEV1< 30% of predicted value (example, diagnosed malignancy).
  16. Any major surgery, major trauma, revascularization procedure, or acute coronary syndrome within the past 3 months.
  17. Serum creatinine ≥ 2.5 mg/dl or estimated GFR ≤ 50cc/min (at screening).
  18. Major (non-carotid) surgery/procedures planned within 3 months after enrollment.
  19. Currently listed or being evaluated for major organ transplantation (i.e. heart, lung, liver, kidney).
  20. Actively participating in another drug or device trial that has not completed follow-up.
  21. Inability to understand and cooperate with study procedures or provide informed consent.
  22. Non-atherosclerotic carotid stenosis (dissection, fibromuscular dysplasia, or stenosis following radiation therapy).
  23. Previous ipsilateral CEA or CAS.
  24. Ipsilateral internal or common carotid artery occlusion.
  25. Intra-carotid floating thrombus.
  26. Ipsilateral intracranial aneurysm > 5mm.
  27. WHO Class III obesity (BMI > 40 kg/m2).
  28. Contra-lateral common or internal carotid artery occlusion.

Specific carotid endarterectomy exclusion criteria

Patients who are being considered for revascularization by CEA must not have any of the following criteria:

  1. Serious adverse reaction to anesthesia not able to be overcome by pre-medication.
  2. Coronary artery disease with two or more proximal or major diseased coronary arteries with greater than or equal to 70% stenosis that have not, or cannot, be revascularized prior to CEA.
  3. Any of the following anatomical exclusions for CEA: radical neck dissection; surgically inaccessible lesions (e.g. above cervical spine level 2 (C2)); adverse neck anatomy that limits surgical exposure (e.g. spinal immobility - inability to flex neck beyond neutral or kyphotic deformity, or short obese neck); presence of tracheostomy stoma; laryngeal nerve palsy contralateral to target vessel; or previous extracranial-intracranial or subclavian bypass procedure ipsilateral to the target vessel.
  4. Known allergy to heparin or bivalirudin.
  5. For age < 50 years, CAS is the favored procedure. However, the CREST results for asymptomatic patients showed wide confidence intervals about the point estimates comparing CAS and CEA. Accordingly, choice of CEA or CAS cannot be mandated; individual patient characteristics and preferences may supersede guidelines based upon patient age. (See Section 8.1.3 for more details)

Specific Carotid Artery Stenting Exclusion Criteria

Patients who are being considered for revascularization by CAS must not have any of the following criteria:

  1. Allergy to intravascular contrast dye not amenable to pre-medication.
  2. Occlusive or critical ilio-femoral disease including severe tortuosity or stenosis that necessitates additional endovascular procedures to facilitate access to the aortic arch or that prevents safe and expeditious femoral access to the aortic arch.
  3. Angiographic, CT, MR or ultrasound evidence of severe atherosclerosis of the aortic arch or origin of the innominate or common carotid arteries.
  4. Type III, calcified aortic arch anatomy.
  5. Qualitative characteristics of stenosis and stenosis-length of the carotid bifurcation (common carotid) and/or ipsilateral external carotid artery, in combination with elements of the exclusions # 3 and 4 that preclude safe sheath placement.
  6. Angulation or tortuosity (≥ 90 degree) of the innominate and common carotid artery that precludes safe, expeditious sheath placement or that will transmit a severe loop to the internal carotid after sheath placement.
  7. Severe angulation or tortuosity of the internal carotid artery (including calyceal origin from the carotid bifurcation) that precludes safe deployment of embolic protection device or stent. Severe tortuosity is defined as 2 or more ≥ 90 degree angles within 4 cm of the target stenosis.
  8. Excessive circumferential calcification of the stenotic lesion defined as > 3mm thickness of calcification seen in orthogonal views on fluoroscopy.
  9. Anatomic considerations such as tortuosity, arch anatomy, and calcification must be evaluated even more carefully in elderly subjects (≥ 70 years).
  10. "String sign" of the ipsilateral common or internal carotid artery.
  11. Lesions > 20 mm in length.
  12. Target ICA vessel reference diameter < 4.0 mm or > 9.0 mm. Target ICA measurements may be made from angiography of the contralateral artery. The reference diameter must be appropriate for the devices to be used.
  13. Inability to deploy or utilize an FDA-approved Embolic Protection Device (EPD).
  14. For age > 74 years, CEA is the favored procedure. However, the CREST results for asymptomatic patients showed wide confidence intervals about the point estimates comparing CAS and CEA. Accordingly, choice of CEA or CAS cannot be mandated; individual patient characteristics and preferences may supersede guidelines based upon patient age)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02089217

Contacts
Contact: CREST-2 Administrative Center 844-956-1826

Locations
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Contact: Mauricia Buchanan, RN    904-953-9455    buchanan.mauricia@mayo.edu   
Principal Investigator: Albert Hakaim, MD         
United States, Kentucky
Baptist Health Lexington Recruiting
Lexington, Kentucky, United States, 40503
Contact: Linda Breathitt    859-260-6344    lbreathitt@bhsi.com   
Contact: Sara Renfrow    859-260-6950    sara.renfrow@bhsi.com   
Principal Investigator: Michael Jones, MD         
United States, Louisiana
Ochsner Health System Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Shannon Williams    504-842-6487      
Principal Investigator: Charles Sternbergh III, MD         
United States, Michigan
Trinity Health/ Michigan Heart Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Cheryl Marentette    734-712-7241      
Principal Investigator: Herbert Aronow, MD         
United States, Missouri
Mercy Hospital Recruiting
St. Louis, Missouri, United States, 63141
Contact: Mary Wilcox    314-251-5916    mary.wilcox@mercy.net   
Principal Investigator: Scott Westfall, MD         
United States, North Carolina
Novant Health/Forsyth Medical Center Recruiting
Winston-Salem, North Carolina, United States, 27103
Contact: Keisha Rodriguez    336-718-6810      
Principal Investigator: Donald Heck, MD         
United States, Ohio
The Christ Hospital Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Roxanne Robertson    513-585-1777    roxanne.robertson@thechristhospital.com   
Principal Investigator: Robert Bulas, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Jon Foley    503-494-8001    foley@ohsu.edu   
Principal Investigator: Wayne Clark, MD         
Sponsors and Collaborators
Thomas G. Brott, M.D.
Investigators
Principal Investigator: Thomas G. Brott, MD Mayo Clinic Florida
Principal Investigator: James F. Meschia, MD Mayo Clinic Florida
Principal Investigator: Brajesh K. Lal, MD University of Maryland
Principal Investigator: George Howard, DrPH University of Alabama at Birmingham
  More Information

Additional Information:
No publications provided

Responsible Party: Thomas G. Brott, M.D., Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT02089217     History of Changes
Other Study ID Numbers: 13-004051, U01 NS080168, IDE: G130221
Study First Received: March 13, 2014
Last Updated: February 24, 2015
Health Authority: United States: Food and Drug Administration
United States: National Institute of Neurological Disorders and Stroke

Keywords provided by Mayo Clinic:
asymptomatic
carotid
stent
endarterectomy
embolic protection
medical management
hypertension
hyperlipidemia
cognition
risk factor control

Additional relevant MeSH terms:
Carotid Stenosis
Arterial Occlusive Diseases
Brain Diseases
Cardiovascular Diseases
Carotid Artery Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on March 01, 2015